BRPI0717744A2 - Ligante de 4-1bb em doenças inflamatórias - Google Patents

Ligante de 4-1bb em doenças inflamatórias Download PDF

Info

Publication number
BRPI0717744A2
BRPI0717744A2 BRPI0717744-5A BRPI0717744A BRPI0717744A2 BR PI0717744 A2 BRPI0717744 A2 BR PI0717744A2 BR PI0717744 A BRPI0717744 A BR PI0717744A BR PI0717744 A2 BRPI0717744 A2 BR PI0717744A2
Authority
BR
Brazil
Prior art keywords
1bbl
amino acid
polypeptide
seq
blocking agent
Prior art date
Application number
BRPI0717744-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Young Jun Kang
Jiahuai Han
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI0717744A2 publication Critical patent/BRPI0717744A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
BRPI0717744-5A 2006-10-16 2007-10-16 Ligante de 4-1bb em doenças inflamatórias BRPI0717744A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85202206P 2006-10-16 2006-10-16
US60/852,022 2006-10-16
US91756107P 2007-05-11 2007-05-11
US60/917,561 2007-05-11
PCT/US2007/022103 WO2008057171A2 (en) 2006-10-16 2007-10-16 4-1 bb ligand in inflammatory diseases

Publications (1)

Publication Number Publication Date
BRPI0717744A2 true BRPI0717744A2 (pt) 2013-11-12

Family

ID=39364965

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717744-5A BRPI0717744A2 (pt) 2006-10-16 2007-10-16 Ligante de 4-1bb em doenças inflamatórias

Country Status (11)

Country Link
US (1) US20100098689A1 (enExample)
EP (1) EP2097454A2 (enExample)
JP (1) JP2010506921A (enExample)
KR (1) KR20090068376A (enExample)
AU (1) AU2007318219A1 (enExample)
BR (1) BRPI0717744A2 (enExample)
CA (1) CA2666306A1 (enExample)
IL (1) IL197637A0 (enExample)
MX (1) MX2009004021A (enExample)
RU (1) RU2009110153A (enExample)
WO (1) WO2008057171A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248157A1 (en) * 2001-09-14 2004-12-09 Michal Ayalon-Soffer Novel polynucleotides encoding soluble polypeptides and methods using same

Also Published As

Publication number Publication date
JP2010506921A (ja) 2010-03-04
IL197637A0 (en) 2011-08-01
WO2008057171A2 (en) 2008-05-15
KR20090068376A (ko) 2009-06-26
EP2097454A2 (en) 2009-09-09
CA2666306A1 (en) 2008-05-15
MX2009004021A (es) 2009-08-12
US20100098689A1 (en) 2010-04-22
WO2008057171A3 (en) 2008-11-20
AU2007318219A1 (en) 2008-05-15
RU2009110153A (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
Yagi et al. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells
Semmrich et al. Importance of integrin LFA-1 deactivation for the generation of immune responses
EP1469879B1 (en) Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
US20100183633A1 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
Fan et al. Treatment of collagen‐induced arthritis with an anti‐osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells
US20080241130A1 (en) Methods and compositions for modulating il-17f/il-17a biological activity
EP1378749A1 (en) Screening method
BRPI0612419A2 (pt) método para tratar infecção por rhabdovirus em um sujeito mamìfero suspeito de ter uma infecção, método para tratar uma doença autoimune em um sujeito mamìfero, método para tratar inflamação em um sujeito mamìfero, método para identificar um modulador de sinalização em células via uma trajetória de recpetor "tool-like" 4, método para selecionar um composto para tratar uma doença infecciosa, método para selecionar um composto para tratar uma doença autoimune, método para selecionar um composto para tratar inflamação, animal não humano transgênico, célula ou linha de células, método para seleção in vitro de um modulador de atividade de sinalização de receptor "tool-like" 4 ou de tram-trif e método para seleção in vivo de um modulador de atividade de sinalização de receptor "tool-like" 4 ou de tram-trif
Nollet et al. Involvement of multiple variants of soluble CD146 in systemic sclerosis: identification of a novel profibrotic factor
WO2022152715A1 (en) Inhibitors of trpm3 and their uses
CN101528779A (zh) 炎症性疾病中的4-1bb配体
US20100098689A1 (en) 4-1 bb ligand in inflammatory diseases
US20230220037A1 (en) Novel use
WO2024013052A1 (en) Novel use
WO2009053481A1 (en) Compositions and methods for modulating nk and t cell trafficking
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
US7892755B2 (en) Screening method
HK1134304A (en) 4-1 bb ligand in inflammatory diseases
CN103370338B (zh) Myomegalin变体8及其应用
US7432343B2 (en) Diagnostic application of mail
US20060063711A1 (en) Use of sglt homolog
WO2005046565A2 (en) Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
Abreu et al. Research article A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis
JP2021097682A (ja) Ｃａｒｄ１４を用いた治療、診断およびスクリーニング

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.